CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 60,000 shares at an average $30.93 ($1,855,839)
- 4 Planned sale Chief Legal Officer and GC sold 10,000 shares at $30.00 ($300,000)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Legal Officer and GC sold 10,000 shares at $28.09 ($280,861)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 60,000 shares at $30.10 ($1,805,766)
- 144 Insider Sale of Securities
- 10-K Report Annual Report
- 4 Planned sale Chief Legal Officer and GC sold 10,000 shares at an average $27.83 ($278,315)
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale CHIEF MEDICAL OFFICER sold 1,779 shares at an average $32.21 ($57,295)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 1,745 shares at an average $32.19 ($56,168)
Page 7 of 65 · 1,286 filings